My feeling is...it worked but not well enough to justify further development (financially), because there are some enrolled patients who had stable disease for more than 6 months...all the patients that showed benefit will still receive the treatment even if the development was discontinued.
LAVA Therapeutics has discontinued development of LAVA-1207 for PSMA-positive metastatic castration-resistant prostate cancer after its phase 1/2a trial fell short of internal benchmarks. The study, which involved dose-escalation and combination arms with pembrolizumab or low-dose IL-2, showed PSA reductions in some patients and confirmed the agent’s tolerability. However, the results did not justify further development. LAVA-1207 was designed to engage Vδ2 T cells to target prostate cancer cells, but its limited efficacy led the company to reprioritize its pipeline. LAVA will now focus on LAVA-1266 for hematologic cancers and continue supporting partnered programs. Although LAVA-1207 is no longer in active development, its trial provided important insights into gamma-delta T-cell therapies.
Robust PSA Drops With Radionuclide Therapy in CRPCa— All but one patient had a PSA decline after a fractionated dose of 225Ac-J591
Statins 'could treat prostate cancer': Cholesterol-busting drugs starve stubborn tumours, first of its kind trial finds